AstraZeneca shares results from phase 3 trial of acoramidis in adults with ATTR-CM
Betsy Goodfellow | February 2, 2024 | News story | Research and Development | ATTR-CM, AstraZeneca, Cardiology, acoramidis, clinical trial
AstraZeneca has announced positive high-level results from the phase 3 trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in Japan. The trial results showed consistency to those from the global BridgeBio Pharma ATTRibute-CM phase 3 trial.
The results covered survival, cardiac related hospitalisations and other measures of improved functions and quality of life at 30 months. The trial in Japan was initiated in order to support registration in the country.
Alexion, AstraZeneca’s Rare Disease division, has an exclusive licence with BridgeBio’s affiliate, Eidos Therapeutics, for the development and commercialisation of acoramidis in Japan.
Professor Yukio Ando MD PhD, department of Amyloidosis Research, Nagasaki International University, Japan, commented: “As people living with ATTR-CM are at risk of significant morbidity and mortality, including heart failure, halting disease progression is essential to improving outcomes. These results offer further evidence that TTR stabilisation with acoramidis may improve survival and reduce disease severity for patients by preventing further breakdown of these proteins.”
Marc Dunoyer, chief executive officer of Alexion, AstraZeneca Rare Disease, added: “With one of the industry’s largest amyloidosis pipelines exploring multiple therapeutic modalities, we are working to redefine treatment and care as well as offer new hope for this underserved community. These positive results support our ambition to bring acoramidis to people living with ATTR-CM in Japan as soon as possible.”
Betsy Goodfellow
Related Content
Gilead shares phase 3 results from HIV prevention trial
Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE …
Takeda shares data from phase 3 trial of CIPD treatment
Takeda has announced data from the phase 3 ADVANCE-CIDP 3 trial, which assessed the safety …
First patient dosed in Assembly Biosciences’ phase 1b trial for hepatitis B treatment
Assembly Biosciences has announced that the first participant has been dosed in its phase 1b …
